213 related articles for article (PubMed ID: 29888855)
1. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A.
Zong Y; Antovic A; Soutari NMH; Antovic J; Pruner I
TH Open; 2020 Apr; 4(2):e94-e103. PubMed ID: 32704613
[TBL] [Abstract][Full Text] [Related]
3. The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.
Schultz NH; Glosli H; Bjørnsen S; Holme PA
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12561. PubMed ID: 34263107
[TBL] [Abstract][Full Text] [Related]
4. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
Kizilocak H; Marquez-Casas E; Malvar J; Young G
Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
[TBL] [Abstract][Full Text] [Related]
6. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
[TBL] [Abstract][Full Text] [Related]
8. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
Bravo MI; Raventós A; Pérez A; Costa M; Willis T
J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
[TBL] [Abstract][Full Text] [Related]
9. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
[TBL] [Abstract][Full Text] [Related]
11. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model.
Pittman DD; Rakhe S; Bowley SR; Jasuja R; Barakat A; Murphy JE
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12679. PubMed ID: 35316941
[TBL] [Abstract][Full Text] [Related]
13. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
Livnat T; Sehgal A; Qian K; Van Nguyen H; Madigan K; Sorensen B; Kenet G
Blood Cells Mol Dis; 2020 May; 82():102416. PubMed ID: 32066048
[TBL] [Abstract][Full Text] [Related]
16. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
[TBL] [Abstract][Full Text] [Related]
17. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
18. Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay.
Tran HTT; Sørensen B; Bjørnsen S; Pripp AH; Tjønnfjord GE; Andre Holme P
Haemophilia; 2015 Mar; 21(2):275-283. PubMed ID: 25521720
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
Linari S; Castaman G
Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
[TBL] [Abstract][Full Text] [Related]
20. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
